Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, […]